Company: BKYI
Filing Date: 2025-04-23
Form Type: 10-K
Source: 0001437749-25-012824
Chunk: 51

Company: BIO KEY INTERNATIONAL INC
Filing Date: 2025-04-23
Form: 10-K
Item: Item 1A
Chunk 51
---
, consultants, advisors and independent contractors of the Company. Options are issued at exercise prices which may not be below 100% of fair market value (or 110% of the fair market value if, at the time the option is granted, the participant owns, directly or indirectly, more than 10% of the total combined voting power of all classes of our stock) and have terms not to exceed ten years. Options issued under the 2023 Plan vest pursuant to the terms of stock option agreements with the recipients. In the event of a change in control, certain awards issued under this plan may be subject to additional acceleration of vesting as may be provided in the participants’ written agreement or as determined by the Board or Compensation Committee. The 2023 Plan expires on December 13, 2033, unless terminated earlier. Awards have been granted for 185,194 shares under the 2023 Plan in 2024.

      Number 

      of securities 

      remaining 

      available for 

      Number of 

      future issuance 

      securities to be 

      Weighted- 

      under equity 

      issued 

      average 

      compensation 

      upon exercise 

      exercise price 

      plans 

      of outstanding 

      of outstanding 

      (excluding 

      options, 

      options, 

      securities 

      warrants and 

      warrants and 

      reflected in 

      rights 

      rights 

      column (a)) 

      Plan Category 
      
      (a) 

      (b) 

      (c) 

      Equity compensation plans approved by security holders 

     3,007
      
      (1)(2) 
      
     $
     197.31

     190,285
      
      (3) 

      Equity compensation plans not approved by security holders 

     —

     $
     -

     —

      Total 

     3,007
      
      (1)(2) 
      
     $
     197.31

     190,285
      
      (3) 

      (1) 
      Consists of shares of common stock issuable upon the exercise of options outstanding as of December 31, 2024 under the 2015 Plan and the 2023 Plan. 

      (2) 
      Excludes employee stock purchase rights accruing under the ESPP. 

      (3) 
      Amount includes 529 shares of common stock and 155,957 shares of common stock available as of December